Skin Care Firms Get External Analgesic Treatment In FDA Warning Letters
Executive Summary
Firms marketed products with label and other claims rendering them drugs but containing ingredients and label indications not part of OTC external analgesic TFM, recent warning letters say. Each firm also advised about GMP problems based on findings from Office of Regulatory Affairs' inspections and asked to hire regulatory consultants and provide detailed CAPAs.
You may also be interested in...
Wild Child Netted Down Under In US FDA Initiative To Inspect All Drug Facilities
FDA says Wild Child, which provides products as a contract manufacturer and for private label sales, violated drug GMPs for products including sun care, lice treatment and acne lotion and attempted to avoid US testing standards by relying on Australian mandates.
Scientific Solutions Global's Formulations Miss OTC Monographs Mark – FDA
Firms' BioTemper, bare and Urea brand products, as formulated and labeled, are unapproved drugs that need approval through NDAs before being sold in US, FDA says in warning. Separate websites firm operates for each brand continues offering sales.
FDA Puts Squeeze On SnugZ; Promo Product/OTC Drug Manufacturer Warned For CGMP Violations
Known for its customizable lanyards and eyewear retainers, SnugZ USA, Inc. also manufactures sunscreens and other personal-care items for corporate branding purposes. The FDA inspected the firm’s West Jordan, Utah facility in late 2018, finding significant violations of current good manufacturing practices, according to a warning letter posted to the agency’s website 9 July.